PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
26.95%
R&D growth less than half of GNPX's 333.47%. David Dodd would verify if efficiency advantage is sustainable.
24.63%
G&A growth while GNPX reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
Other expenses change of 3.65% while GNPX maintains costs. Bruce Berkowitz would investigate efficiency.
26.14%
Operating expenses growth while GNPX reduces costs. John Neff would investigate differences.
26.14%
Total costs growth while GNPX reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
3.65%
D&A growth less than half of GNPX's 46.29%. David Dodd would verify if efficiency is sustainable.
-26.20%
EBITDA decline while GNPX shows 63.77% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Operating income decline while GNPX shows 63.60% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.70%
Other expenses reduction while GNPX shows 144.55% growth. Joel Greenblatt would examine advantage.
-26.43%
Pre-tax income decline while GNPX shows 63.93% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.43%
Net income decline while GNPX shows 63.93% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-26.52%
EPS decline while GNPX shows 66.81% growth. Joel Greenblatt would examine position.
-26.52%
Diluted EPS decline while GNPX shows 66.80% growth. Joel Greenblatt would examine position.
0.09%
Share count reduction exceeding 1.5x GNPX's 8.61%. David Dodd would verify capital allocation.
0.09%
Diluted share reduction exceeding 1.5x GNPX's 8.64%. David Dodd would verify capital allocation.